Aperçu de la consommation à des fins non médicales des médicaments sur ordonnance et des questions de justice pénale au Canada

• Page précédente
• Table des matières

Bibliographie

• Addictions Services Regina Qu'Appelle Health Region (2006). CCENDU Regina and Area 2004 Report Regina: Centre canadien de lutte contre les toxicomanies.

• Adlaf, E. et Pagila-Boak, A. (2005). Drug Use Among Ontario Students 1977-2005: OSDUS highlights. http://www.camh.ca/en/research/news_and_publications/ontario-student-drug-use-and-health-survey/Documents/2011%20OSDUHS%20Docs/2011OSDUHS_Highlights_DrugUseReport.pdf (anglais seulement) [En ligne].

• Adlaf, E. M. et Paglia-Boak, A. (2007). Drug use among Ontario students: Detailed OSDUHS findings: 1977-2007. http://www.camh.ca/en/hospital/Documents/www.camh.net/OSDUHS2007_DrugDetailed_final.pdf (anglais seulement) [En ligne].

• Adlaf, E. M., Paglia-Boak, A. et Brands, B. (2006). Use of OxyContin by adolescent students. Journal de l'Association médicale canadienne, 174, p. 1303.

• Adlaf, E., A. Demers et L. Gliksman (2005b). Enquête sur les campus canadiens, 2004, Toronto, Centre de toxicomanie et de santé mentale.

• Adlaf, E., P. Begin et E. Sawka (2005a). Enquête sur les toxicomanies au Canada (ETC) : une enquête nationale sur la consommation d’alcool et d’autres drogues par les Canadiens : la prévalence de l’usage et les méfaits : rapport détaillé. http://www.ccsa.ca/2005%20CCSA%20Documents/ccsa-004029-2005.pdf (anglais seulement) [En ligne].

• Anonyme (2005). Prescription opioid addiction leads many to methadone treatment. Alcoholism and Drug Abuse Weekly, 17, 1-3-5.

• Anthony, J., Warner, L. et Kessler, R. (1994). Comparative epidemiology of dependence on tobacco, alcohol, controlled substances, and inhalants: Basic findings from the national comorbidity survey. Experimental & Clinical Psychopharmacology, 2, p. 244 à 268.

• Babor, T., Caetano, R., Casswell, S., Edwards, G., Giesbrecht, N., Graham, K. et al. (2003). Alcohol: no ordinary commodity. Research and public policy. Oxford and London: Oxford University Press.

• Banta-Green, C., Merrill, J., Doyle, S., Boudreau, D. et Calsyn, D. (2009). Measurement of opioid problems among chronic pain patients in a general medical population. Drug and Alcohol Dependence, 104, p. 43 à 49.

• Barrett, S., Darredeau, C. et Pihl, R. (2006). Patterns of simultaneous polysubstance use in drug using university students. Human Psychopharmacology, 21, p. 255 à 263.

• Beare, M. (2002). Organized corporate criminality - Tobacco smuggling between Canada and the US. Crime, Law and Social Change, 37, p. 225 à 243.

• Beau Dietl et associés (2006). "You've Got Drugs!" Prescription drug pushers on the Internet: 2006 update. A CASA White Paper. New York: The National Center on Addiction and Substance Abuse at Columbia University.

• Becker, W., Fiellin, D. et Desai, R. (2007). Non-medical use, abuse and dependence on sedatives and tranquilizers among U.S. adults: Psychiatric and socio-demographic correlates. Drug and Alcohol Dependence, 90, p. 280 à 287.

• Becker, W., Sullivan, L., Tetrault, J., Desai, R. A. et Fiellin, D. A. (2008). Non-medical use, abuse and dependence on prescription opioids among U.S. adults: Psychiatric, medical and substance use correlates. Drug and Alcohol Dependence, 94, p. 38 à 47.

• Bennett, D. et Carr, D. (2001). Opiophobia as a barrier to the treatment of pain. Journal of Pain and Palliative Care Pharmacotherapy, 16, p. 105 à 109.

• Birnbaum, H., White, A., Reynolds, J., Greenberg, P., Zhang, M., Vallow, S. et al. (2006). Estimated costs of prescription opioid analgesic abuse in the United States in 2001: A societal perspective. The Clinical Journal of Pain, 22, p. 667 à 676.

• Boyd, C. J., McCabe, S. E. et Teter, C. J. (2006). Medical and nonmedical use if prescription pain medication by youth in a Detroit area public school district. Drug and Alcohol Dependence, 81, p. 37 à 45.

• Boyd, CJ., McCabe, S. E., Cranford, JA. et Young, A. (2007). Prescription drug abuse and diversion among adolescents in a Southeast Michigan school district. Archives of Pediatrics & Adolescent Medicine, 161, p. 276 à 281.

• Boyer, E. et Wines, J. (2008). Impact of internet pharmacy regulation on opioid analgesic availability. Journal of Studies on Alcohol and Drugs 69[5], p. 703 à 708.

• Brands, B., Blake, J. et Marsh, D. (2002). Changing patient characteristics with increased methadone maintenance availability. Drug and Alcohol Dependence, 66, p. 11 à 20.

• Brands, B., Blake, J., Sproule, B., Gourlay, D. et Busto, U. (2004). Prescription opioid abuse in patients presenting for methadone maintenance treatment. Drug and Alcohol Dependence, 73, p. 199 à 207.

• Brands, B., Sproule, B. et Marshman, J. (1998). Drugs and Drug Abuse: A Reference Text. Toronto : Fondation de la recherche sur la toxicomanie. 3^rd Edition.

• Brushwood, D. (2003). Maximizing the value of electronic prescription monitoring programs. The Journal of Law, Medicine and Ethics, 31, p. 41 à 54.

• Busto, U. et Sellers, E. (1991). Pharmacologic aspects of benzodiazepine tolerance and dependence. Journal of Substance Abuse Treatment, 8, p. 29 à 33.

• Busto, U., Bendayan, R. et Sellers, E. (1989). Clinical pharmacokinetics of non-opiate abused drugs. Clinical Pharmacokinetics, 16, p. 1 à 26.

• Busto, U., Romach, M. et Sellers, E. (1996). Multiple drug use and psychiatric comorbidity in patients admitted to the hospital with severe benzodiazepine dependence. Journal of Clinical Psychopharmacology, 16, p. 51 à 57.

• Charlson, F., Degenhardt, L., McLaren, J., Hall, W. et Lynskey, M. (2009). A systematic review of research examining benzodiazepine-related mortality. Pharmacoepidemiology and Drug Safety, 18, 93 à 108.

• CHASE Project Team (2005). Community Health And Safety Evaluation (CHASE) Project: Final report Vancouver: Vancouver Coastal Health Authority.

• Cicero, T. J., Lynskey, M., Todorov, A., Inciardi, J. A. et Surratt, H. L. (2008a). Co-morbid pain and psychopathology in males and females admitted to treatment for opioid analgesic abuse. Pain, 139, p. 127 à 135.

• Cicero, T. J., Shores, C., Paradis, A. et Ellis, M. (2008b). Source of drugs for prescription opioid analgesic abusers: A role for the internet? Pain Medicine 9[6], p. 718 à 723.

• College of Physicians and Surgeons of Alberta: (2004). Triplicate Prescription Program: Information for the pharmacist. http://www.cpsa.ca/wp-content/uploads/2015/09/Information_for_prescribers_and_dispensers.pdf (anglais seulement) [En ligne].

• Community Epidemiology Work Group (2008). Epidemiologic trends in drug abuse: Proceedings of the Community Epidemiology Work Group. Volume II Bethesda, MD: Division of Epidemiology, Services and Prevention Research. National Institutes of Health.

• Compton, W. M. et Volkow, N. D. (2006). Major increases in opioid analgesic abuse in the United States: concerns and strategies. Drug and Alcohol Dependence, 81, p. 103 à 107.

• Covell, K. (2004). Adolescents and drug use in Cape Breton: A focus on risk factors and prevention Cape Breton: Children's Rights Centre, University College of Cape Breton.

• Curtis, L., Stoddard, J., Radeva, J., Hutchison, S., In, P., Wright, A. et al. (2006). Geographic variation in the prescription of schedule II opioid analgesics among outpatients in the United States. Health Services Research, 41, p. 837 à 855.

• Darke, A. et Stewart, J. (1999). Efficacy and abuse potential of opioid analgesics and the treatment of chronic noncancer pain. Pain Research and Management, 4, p. 104 à 109.

• Darke, S. et Zador, D. (1996). Fatal heroin "overdose": a review. Addiction, 91, p. 1764 à 1772.

• Darke, S., Degenhardt, L. et Mattick, R. (2007). Mortality amongst illicit drug users: Epidemiology, causes and intervention. Cambridge: Cambridge University Press.

• Dauvergne, M. (2009). Tendances des infractions relatives aux drogues déclarées par la police au Canada, Juristat, 29.

• Davis, W. et Johnson, B. (2008). Presciption opioid use, misuse, and diversion among street drug users in New York City. Drug and Alcohol Dependence, 92, p. 267 à 276.

• Dekker, A. (2007). What is being done to address the new drug epidemic? Journal of the American Osteopathic Association, p. 107, ES21 à ES26.

• Department of Health and Human Services (2009). Treatment Episode Data Sets (TEDS) Highlights - 2007. National admissions to substance abuse treatment services. http://wwwdasis.samhsa.gov/teds07/tedshigh2k7.pdf (anglais seulement) [En ligne].

• Dhalla, I., Mamdani, M., Sivilotte, M., Kopp, A., Qureshi, O. et Juurlink, D. (2009). Opioid analgesic prescribing and mortality before and after the introduction of long-acting oxycodone in Ontario. Journal de l'Association médicale canadienne, publié; vol. 181, n^o 12, p. 891 à 896. Voir http://www.cmaj.ca/content/181/12/891.abstract

• Dowling, K., Storr, C. L. et Chilcoat, H. D. (2006). Potential influences on initiation and persistence of extramedical prescription pain reliever use in the US population. Clinical Journal of Pain, 22, p. 776 à 783.

• Drogue et alcool – Système d’information sur le traitement (DASIT) (2008). Substance abuse statistical tables. http://www.datis.ca/pub/reports/DATIS%20Substance%20Abuse%20Statistical%20Tables%20FY200708%20to%20FY201112.pd f (anglais seulement) [En ligne].

• Egger M, Smith GD, Altman DG (2001). Systematic reviews in health care. Meta-analysis in context. London, UK: BMJ Books.

• El-Aneed, A., Alaghehbandan, R., Gladney, N., Collins, K., MacDonald, D. et Fischer, B. (2009). Prescription drug abuse and methods of diversion: The potential role of a pharmacy network. J Subst Use, 14, p. 75 à 83.

• Epidemiology and Disease Control and Population Health Surveillance Unit (2006). I-Track Survey: Enhanced surveillance of risk behaviours and prevalence of HIV and hepatitis C among people who inject drug: Victoria site report Victoria: Vancouver Island Health Authority and Agence de la santé publique du Canada.

• Fanton, L., Bévalot, F., Schoendorff, P., Lalliard, S., Jdeed, K. et Malicier, D. (2007). Toxicologic aspects of deaths due to falls from height. American Journal of Forensic Medical Pathology, 28, p. 262 à 266.

• Fernandez, C., Stutzer, C., MacWilliam, L. et Fryer, C. (1998). Alternative and complementary therapy use in pediatric oncology in British Columbia: prevalence and reasons for use and nonuse. Journal of Clinical Oncology, 16, p. 1279 à 1286.

• Firestone-Cruz, M. et Fischer, B. (2008). A qualitative exploration of prescription opioid injection among street-based drug users in Toronto: behaviours, preferences and drug availability. Harm Reduction Journal, 5, p. 30.

• Fischer, B. (1999). Prohibition, public health and a window of opportunity: An analysis of Canadian drug policy, 1985-1997. Policy Studies, 20, p. 197 à 210.

• Fischer, B. (2003). Illegale Opiatsucht, Behandlung und ökonomische Kostenforschung - ein beispielhafter Überblick und eine Diskussion aus sozialwissenschaftlicher Perspektive [Illicit opioid dependence, treatment and economic cost research - a selective review and discussion from a social science perspective]. Sucht, 4, p. 2 à 7.

• Fischer, B. et Rehm, J. (2008). Nonmedical use of prescription opioids: Furthering a meaningful research agenda. J Pain, 9, p. 490 à 493.

• Fischer, B., Brissette, S., Brochu, S., Bruneau, J., el-Guebaly, N., Noel, L. et al. (2004). Determinants of overdose incidents among illicit opioid users in 5 Canadian cities. Journal de l'Association médicale canadienne, 171, p. 235 à 239.

• Fischer, B., De Leo, J., Allard, C., Firestone Cruz, M., Patra, J. et Rehm J. (2009a). Exploring drug sourcing among regular prescription opioid users in Canada: Data from Toronto and Victoria. Revue canadienne de criminologie et de justice pénale, 51, p. 55 à 72.

• Fischer, B., Gittins, J. et Rehm, J. (2008b). Characterizing the 'awakening elephant': prescription opioid misuse in North America: Epidemiology, harms, interventions. Contemporary Drug Problems, 35, p. 397 à 426.

• Fischer, B., Gittins, J., Kendall, et Rehm J. (2009b). Thinking the unthinkable: Could the increasing misuse of prescription opioids among street drug users offer benefits for public health? Public Health, 123, p. 145 et 146.

• Fischer, B., Manzoni, P. et Rehm, J. (2006a). Comparing injecting and non-injecting illicit opioid users in a multisite Canadian sample (OPICAN cohort). European Addiction Research, 12, p. 230 à 239.

• Fischer, B., Nakamura, N., Rush, B., Rehm, J. et Urbanoski, K. (2009c). Changes in and characteristics of admissions to substance use treatment related to problematic prescription opioid use in Ontario, 2004-2009. Publié dans PubMed à : http://www.ncbi.nlm.nih.gov/pubmed/20197216  (anglais seulement)

• Fischer, B., Patra, J., Firestone Cruz, M., Gittins, J. et Rehm, J. (2008a). Comparing heroin users and prescription opioid users in a Canadian multi-site population of illicit opioid users. Drug and Alcohol Review, 27, p. 625 à 632.

• Fischer, B., Rehm, J., Brissette, S., Brochu, S., Bruneau, J., el-Guebaly, N. et al. (2005). Illicit opioid use in Canada: Comparing social, health and drug use characteristics of untreated users in five cities (OPICAN study). Journal of Urban Health, 82, p. 250 à 266.

• Fischer, B., Rehm, J., Goldman, B. et Popova, S. (2008c). Non-medical use of prescription opioids and public health in Canada: an urgent call for research and interventions development. La Revue canadienne de santé publique, 99, p. 182 à 184.

• Fischer, B., Rehm, J., Patra, J. et Firestone Cruz, M. (2006b). Changes in illicit opioid use profiles across Canada. Journal de l'Association médicale canadienne, 175, p. 1 à 3.

• Fischer, B., Single, E., Room, R., Poulin, C., Sawka, E., Thompson, H. et Topp, J. (1998). Cannabis use in Canada: Policy options for control. Options politiques, p. 34 à 38

• Fishman, S. (2006). Commentary in response to Paulozzi et al: prescription drug abuse and safe pain management. Pharmacoepidemiology and Drug Safety, 15, p. 628 à 631.

• Fishman, S. M., Papazian, J. S., Gonzalez, S., Riches, P. S. et Gilson, A. (2004). Regulating opioid prescribing through prescription monitoring programs: balancing drug diversion and treatment of pain. Pain Medicine, 5, p. 309 à 324.

• Forman, R. F. (2006). Innovations: alcohol & drug abuse: narcotics on the net: the availability of web sites selling controlled substances. Psychiatric Services, 57, p. 24 à 26.

• Friesen, K., Lemaire, J. et Patton, D. (2008). Alcohol and other drugs: Students in Manitoba - 2007 Addictions Foundation of Manitoba.

• Garvin, F. (2004). Safe community coalition of Brockville and District Leeds and Grenville 2004 CCENDU/HEP Report Brockville: Canadian Community Epidemiology Network on Drug Use & Health, Education and Enforcement Partnership.

• Giffen, J., Endicott, S. et Lambert, S. (1991). Panic and Indifference - The Politics of Canada's Drug Laws. Ottawa: Centre canadien de lutte contre les toxicomanies.

• Gilbody, S., Wilson, P. et Watt, I. (2005). Benefits and harms of direct to consumer advertising: a systematic review. BMJ Quality and Safety in Health Care, 14, p. 246 à 250.

• Gilson, A., Ryan, K., Joranson, D. E. et Dahl, J. (2004). A reassessment of trends in the medical use and abuse of opioid analgesics and implications for diversion control. Journal of Pain and Symptom Management, 28, p. 176 à 188.

• Gliksman, L., A. Demers, E.M. Adlaf, B. Newton-Taylor et K. Schmidt (2000). Enquête sur les campus canadiens, 1998, Toronto, Centre de toxicomanie et de santé mentale.

• Goldman, B. (2002). Comportement toxicomane, dans R. Jovey (réd.), La gestion de la douleur : la référence des professionnels canadiens de la santé (p. 77 à 87), Toronto, Rogers Publishing.

• Goldman, B. (2008). Drug-seeking behaviour. In R.Jovey (Ed.), (p. 119 à 136). Toronto: Rogers Media.

• Goldstein, P. (1985). The drugs/violence nexus: A tripartite conceptual framework. Journal of Drug Issues, 15, p. 493 à 506.

• Goodwin, R. et Hasin, D. (2002). Sedative use and misuse in the United States. Addiction, 97, p. 555 à 562.

• Govitrapong, P., Suttitum, T., Kotchabhakdi, N. et Uneklabh, T. (1998). Alternations of immune functions in heroin addicts and heroin withdrawal subjects. Journal of Pharmacology and Experimental Therapeutics, 286, p. 883 à 889.

• GRC Renseignements criminels (2008). Rapport sur la situation des drogues illicites au Canada –2007. http://publications.gc.ca/collections/collection_2012/grc-rcmp/PS61-14-2008-fra.pdf [En ligne].

• Hamilton, I., Reay, L. et Sullivan, F. (1990). A survey of general practitioners' attitudes to benzodiazepine overprescribing. Health Bulletin (Edinb), 48, p. 299 à 303.

• Haydon, E., Rehm, J., Fischer, B., Monga, N. et Adlaf, E. (2005). Prescription Drug Abuse in Canada and the Diversion of Prescription Drugs into the Illicit Drug Market. La Revue canadienne de santé publique, 96, p. 459 à 461.

• Hegeman, J., van den Bemt, B., Duysens, J. et van Limbeek, J. (2009). NSAIDs and the risk of accidental falls in the elderly: a systematic review. Drug Safety, 32, p. 489 à 498.

• Hollenberg, D. (2006). Uncharted ground: Patterns of professional interaction among complementary/alternative and biomedical practitioners in integrative health care settings. Social Science and Medicine, 62, p. 731 à 744.

• Huang, B., Dawson, D., Stinson, F. S., Hasin, D. S., Ruan, W., Saha, T. et al. (2006). Prevalence, correlates, and comorbidity of nonmedical prescription drug use and drug use disorders in the United States: Results of the National Epidemiologic Survey on Alcohol and Related Conditions. Journal of Clinical Psychiatry, 67, p. 1062 à 1073.

• Hurwitz, W. (2005). The challenge of prescription drug misuse: A review and commentary. Pain Medicine, 6, p. 152 à 161.

• Ialomiteanu, A et Adlaf, E.M. (2009). CAMH Monitor 2008: Technical Guide. Toronto, Centre de toxicomanie et de santé mentale. http://www.camh.ca/en/research/Documents/www.camh.net/Research/Areas_of_research/Population_Life_Course_Studies/CAMH_Monitor/CM2008_TechDoc.pdf (anglais seulement) [En ligne, données non publiées]

• Ialomiteanu, A.R., Adlaf, E.M., Mann, R.E. et Rehm J. (2009). CAMH Monitor eReport.Addiction and mental health indicators among Ontario adults 1977-2007. Toronto: Centre de toxicomanie et de santé mentale.

• Inciardi, J. A., Surratt, H. L., Kurtz, S. P. et Burke, J. (2006). The diversion of prescription drugs by health care workers in Cincinnati, Ohio. Substance Use and Misuse, 41, p. 255 à 264.

• Inciardi, J., Surratt, H. L., Cicero, T. J. et Beard, R. (2009). Prescription opioid abuse and diversion in an urban community: The results of an ultrarapid assessment. Pain Medicine, 10, p. 537 à 548.

• Inciardi, J., Surratt, H. L., Kurtz, S. et Cicero, T. J. (2007). Mechanisms of prescription drug diversion among drug-involved club- and street-based populations. Pain Medicine, 8, p. 171 à 183.

• Jerian, K. (2006). What's a legal system to do? The problem of regulating Internet pharmacies. Albany Law Review of Science and Technology, 16, p. 571 à 598.

• Joossens, L. et Raw, M. (2000). How can cigarette smuggling be reduced? British Medical Journal, 321, p. 947 à 950.

• Joranson, D. E. et Gilson, A. (2006). Wanted: a public health approach to prescription opioid abuse and diversion. Pharmacoepidemiology and Drug Safety, 15, p. 632 à 634.

• Joranson, D. E. et Gilson, A. (2007). A much-needed window on opioid diversion. Pain Medicine, 8, p. 128 et 129.

• Joranson, D., Carrow, G., Ryan, K., Shaefer, L., Gilson, A., Good, P. et al. (2002). Pain management and prescription monitoring. Journal of Pain and Symptom Management, 23, p. 231 à 238.

• Kaye, S., Darke, S., Duflou, J. et McKetin, R. (2008). Methamphetamine-related fatalities in Australia: demographics, circumstances, toxicology and major organ pathology. Addiction, 103, p. 1353 à 1360.

• Kelly, E., Darke, S. et Ross, J. (2004). A review of drug use and driving: epidemiology, impairment, risk factors and risk perceptions. Drug and Alcohol Review, 23, p. 319 à 344.

• Khantzian, E. J. (1997). The self-medication hypothesis of substance use disorders: a reconsideration and recent applications. Harvard Review of Psychiatry, 4, p. 231 à 224.

• Lane, J. et AADAC Research Services (2006). The Alberta Youth Experience Survey (TAYES) 2005 Alberta Alcohol and Drug Abuse Commission (AADAC).

• Lankenau, S. E., Sanders, B., Jackson Bloom, J., Hathazi, D., Alarcon, E., Tortu, S. et al. (2007). Prevalence and patterns of prescription drug misuse among young ketamine injectors. Journal of Drug Issues, 37, p. 717 à 736.

• Lenton, S. et Heale, P. (2000). Arrest, court and social impacts of conviction for a minor cannabis offence under strict prohibition. Contemporary Drug Problems, 27, p. 805 à 833.

• Lenton, S., Humeniuk, R., Heale, P. et Christie, P. (2000). Infringement versus conviction: the social impact of a minor cannabis offence in South Australia and Western Australia. Drug and Alcohol Review, 19, p. 257 à 264.

• Leri, F., Stweart, J., Fischer, B., Rehm, J. et al (2005). Patterns of opioid and cocaine co-use: A descriptive study in a Canadian sample of untreated opioid-dependent individuals. Experimental & Clinical Psychopharmacology, 13, p. 303 à 310.

• Levy, M. (2007). An exploratory study of OxyContin use among individuals with substance use disorder. Journal of Psychoactive Drugs, 39, p. 271 à 276.

• Littlejohn, C., Baldacchino, A., Schifano, F. et Deluca, P. (2005). Internet pharmacies and online prescription drug sales: A cross-sectional study. Drugs: Education, Prevention & Policy, 12, p. 75 à 80.

• MacCoun, R. et Reuter, P. (2001). Drug War Heresies: Learning from other vices, times, and places. Cambridge University Press.

• Maddox, L. et Katsanis, L. (1997). Direct-to-consumer advertising of prescription drugs in Canada: Its potential effect on patient-physician interaction. Journal of Pharmaceutical Marketing and Management, 12, p. 1 à 21.

• Manzoni, P, Brochu, S, Fischer, B, et Rehm, J (2006). Determinants of Property Crime Among Illicit Opiate Users Outside of Treatment Across Canada. Deviant Behaviour, 27, p. 351 à 376.

• Martin, C. (2008). Prescription drug abuse in the elderly. Consultant Pharmacist, 23, p. 930 à 934.

• Martin, T. L., Woodall, K. L. et McLellan, B. A. (2006). Fentanyl-related deaths in Ontario, Canada: Toxicological findings and circumstances of death in 112 cases (2002-2004). J Analytical Toxicology, 30, p. 603 à 610.

• Martyres, R. F., Clodes, D. et Burns, J. M. (2004). Seeking drugs or seeking help? Escalating "doctor shopping" by young heroin users before fatal overdose. Medical Journal of Australia, 180, p. 211 à 214.

• Maurer, H. (2009). Mass spectrometric approaches in impaired driving toxicology. Analytical and Bioanalytical Chemistry, 393, p. 97 à 107.

• McCabe, S. E. et Boyd, C. J. (2005). Sources of prescription drugs for illicit use. Addictive Behaviors, 30, p. 1342 à 1350.

• McCabe, S. E., Boyd, C. J. et Teter, C. J. (2006). Medical use, illicit use, and diversion of abusable prescription drugs. Journal of American College Health, 54, p. 269 à 278.

• McCabe, S. E., Cranford, JA., Boyd, CJ. et Teter, CJ. (2007). Motives, diversion and routes of administration associated with nonmedical use of prescription opioids. Addictive Behaviors, 32, p. 562 à 575.

• Miller, N., Greenfeld et A (2004). Patient characteristics and risk factors for development of dependence on hydrocodone and oxycodone. American Journal of Therapeutics, 11, p. 26 à 32.

• Mintzes, B., Barer, M., Kravitz, R., Kazanjian, A., Bassett, K., Lexchin, J. et al. (2002). Influence of direct to consumer pharmaceutical advertising and patients' requests on prescribing decisions: two site cross sectional survey. British Medical Journal, 324, p. 278 et 279.

• Mitka, M. (2000). Abuse of prescription drugs: Is a patient ailing or addicted? Journal of the American Medical Association, 283, p. 1126 et 1127.

• Monga, N., Rehm, J., Fischer, B., Brissette, S., Bruneau, J., el-Guebaly, N. et al. (2007). Using latent class analysis (LCA) to analyze patterns of drug use in a population of illegal opioid users. Drug and Alcohol Dependence, 8, p. 1 à 7.

• Morgan, J. (1985). American Opiophobia: Customary underutilization of opioid analgesics. Advances in Alcohol and Substance Abuse, 5, p. 163 à 172.

• Morgan, S., Raymond, C., Mooney, D. et Martin, D. (2008). The Canadian Rx Atlas: 2nd Edition. https://open.library.ubc.ca/cIRcle/collections/ubccommunityandpartnerspublicati/47136/items/1.0228452 (anglais seulement) [En ligne].

• Nielsen, S. et Barratt, M. (2009). Prescription drug misuse: Is technology friend or foe? Drug and Alcohol Review, 28, p. 81 à 86.

• Novak, S., Herman-Stahl, M., Flannery, B. et Zimmerman, M. (2009). Physical pain, common psychiatric and substance use disorders, and the non-medical use of prescription analgesics in the United States. Drug and Alcohol Dependence, 100, p. 63 à 70.

• Office of Diversion Control, U. D. o. J. D. E. A. (2008). Questions and Answers - State prescription drug monitoring programs. http://www.deadiversion.usdoj.gov/faq/rx_monitor.htm (anglais seulement) [En ligne].

• Organe international de contrôle des stupéfiants (2001). Rapport de l’Organe international de contrôle des stupéfiants pour 2001, New York, Organisation des Nations Unies.

• Organe international de contrôle des stupéfiants (2002). Stupéfiants – Évaluations des besoins du monde pour 2003 – Statistiques pour 2001, New York, Organisation des Nations Unies.

• Organe international de contrôle des stupéfiants (2004). Stupéfiants – Évaluations des besoins du monde pour 2005 – Statistiques pour 2003, New York, Organisation des Nations Unies.

• Organe international de contrôle des stupéfiants (2005a). Stupéfiants – Évaluations des besoins du monde pour 2006 – Statistiques pour 2004, New York, Organisation des Nations Unies.

• Organe international de contrôle des stupéfiants (2005b). Substances psychotropes – Statistiques pour 2004 – Prévisions des besoins annuels médicaux et scientifiques concernant les substances des Tableaux II, III et IV de la Convention de 1971 sur les substances psychotropes, New York, Organisation des Nations Unies.

• Organe international de contrôle des stupéfiants (2008a). Stupéfiants – Évaluations des besoins du monde pour 2009 – Statistiques pour 2007. http://www.incb.org/documents/Narcotic-Drugs/Technical-Publications/2008/Narcotics_drugs_publication2008.pdf (anglais seulement) [En ligne].

• Organe international de contrôle des stupéfiants (2008b). Substances psychotropes – Statistiques pour 2007 – Prévisions des besoins annuels médicaux et scientifiques concernant les substances des Tableaux II, III et IV de la Convention de 1971 sur les substances psychotropes, New York, Organisation des Nations Unies.

• Organe international de contrôle des stupéfiants (2009a). Stupéfiants – Évaluations des besoins du monde pour 2009 – Statistiques pour 2007, New York, Organisation des Nations Unies.

• Organe international de contrôle des stupéfiants (2009b). Substances psychotropes – Statistiques pour 2007 – Prévisions des besoins annuels médicaux et scientifiques concernant les substances des Tableaux II, III et IV de la Convention de 1971 sur les substances psychotropes, New York, Organisation des Nations Unies.

• Organe international de contrôle des stupéfiants (2009c). Substances psychotropes – Statistiques pour 2008 – Prévisions des besoins annuels médicaux et scientifiques concernant les substances des Tableaux II, III et IV de la Convention de 1971 sur les substances psychotropes, New York, Organisation des Nations Unies.

• OxyContin Task Force (2004). OxyContin Task Force: Final Report. http://www.health.gov.nl.ca/health/publications/oxycontin_final_report.pdf (anglais seulement) [En ligne].

• Passik, S. D., Hays, L., Eisner, N. et Kirsh, K. (2006). Psychiatric and pain characteristics of prescription drug abusers entreing drug rehabilitation. Journal of Pain and Palliative Care Pharmacotherapy, 20, p. 5 à 13.

• Patra, J., Fischer, B., Maksimowska, S. et Rehm, J. (2009). Profiling poly-substance use typologies in a multi-site cohort of illicit opioid and other drug users in Canada - a latent class analysis (LCA). Addiction Research and Theory, 17, p. 168 à 185.

• Paulozzi, L. et Yongli, X. (2008). Recent changes in drug poisoning mortality in the United States by urban-rural status and by drug type. Pharmacoepidemiology and Drug Safety, 17, p. 997 à 1005.

• Paulozzi, L., Budnitz, D. et Xi, Y. (2006). Increasing deaths from opioid analgesics in the United States. Pharmacoepidemiology and Drug Safety, 15, p. 618 à 627.

• Paulozzi, L., Logan, J., Hall, A., McKinstry, E., Kaplan, J. et Crosby, A. (2009). A comparison of drug overdose deaths involving methadone and other opioid analgesics in West Virginia. Addiction, 104, p. 1541 à 1548.

• Popova, S., Patra, J., Mohapatra, S., Fischer, B. et Rehm J. (2009). How many people in Canada use prescription opioids non-medically in general and street drug using populations? La Revue canadienne de santé publique, 100, p. 104 à 108.

• Poulin, C. et Elliot, D. (2007). Student Drug Use Survey in the Atlantic Provinces 2007: Atlantic Technical Report. http://www.health.gov.nl.ca/health/publications/atl_tech_report_2007_web_cover.pdf (anglais seulement) [En ligne].

• RCCET (2004). Winnipeg 2004 Canadian Community Epidemiology Network on Drug Use Report Winnipeg: RCCET.

• Rehm, J., Baliunas, D., Brochu, S., Fischer, B., Gnam, W., Patra, J. et al. (2006). The costs of substance abuse in Canada 2002. Ottawa, Canada: Centre canadien de lutte contre les toxicomanies (CCLT).

• Research Group on Drug Use (2004). Drug Use in Toronto Toronto: Research Group on Drug Use.

• Rhodin, A. (2006). The rise of opiophobia. Is history a barrier to prescribing? Journal of Pain and Palliative Care Pharmacotherapy, 20, p. 31 et 32.

• Rogers, A., Pilgrim, D., Brennan, S., Sulaiman, I., Watson, G. et Chew-Graham, C. (2007). Prescribing benzodiazepines in general practice: a new view of an old problem. Health, 11, p. 181 à 198.

• Romach, M., Sproule, B., Sellers, E., Somer, G. et Busto, U. (1999). Long-term codeine use is associated with depressive symptoms. Journal of Clinical Psychopharmacology, 19, p. 373 à 376.

• Room, R., Fischer, B., Hall, W., Lenton, S. et Reuter, P. (2008). The Global Cannabis Commission Report: Cannabis Policy: Moving beyond Stalemate Oxford: Beckley Foundation and Oxford University Press.

• Rosenblum, A., Parrino, M., Schnoll, S., Fong, C., Maxwell, C., Cleland, C. et al. (2007). Prescription opioid abuse among enrollees into methadone maintenance treatment. Drug and Alcohol Dependence, 90, p. 64 à 71.

• Rush, B. (2002). Client characteristics and patterns of service utilization within Ontario's specialized addiction treatment agencies: A provincial report from DATIS. 1^er avril 1999 - 31 mars 2000. http://www.datis.ca/download/DATISClientCharReport.pdf.

• Sajan, A., Corneil, T. et Grzybowski, S. (1998). The street value of prescription drugs. Journal de l'Association médicale canadienne,  159, p. 139 à 142.

• SAMHSA (2006). The NSDUH Report: How young adults obtain prescription pain relievers for nonmedical usage SAMHSA.

• Santé Canada (2004). I-Track : surveillance améliorée des comportements à risque chez les utilisateurs de drogues injectables au Canada : rapport sur l’enquête pilote. http://library.catie.ca/PDF/P8/21250.pdf (anglais seulement) [En ligne].

• Santé Canada (2006). I-Track : surveillance améliorée des comportements à risque chez les utilisateurs de drogues injectables au Canada : rapport sur la phase I. http://library.catie.ca/PDF/P36/23689.pdf [En ligne].

• Santé Canada (2009). Enquête de surveillance canadienne de la consommation d'alcool et de drogues : sommaire des résultats pour 2008. http://www.hc-sc.gc.ca/hc-ps/drugs-drogues/stat/_2008/summary-sommaire-fra.php (anglais seulement) [En ligne].

• Schepis, T. et Krishnan-Sarin, S. (2008). Characterizing adolescent prescription misusers: A population-based study. Journal of the American Academy of Child & Adolescent Psychiatry,  47, p. 745 à 754.

• Schiralli, V. et McIntosh, M. (1987). Benzodiazepines: Are we overprescribing? Médecin de famille canadien, 33, p. 927 à 933.

• Shea BJ, Grimshaw JM, Wells GA, Boers M, Andersson N, Hamel C, Porter AC, Tugwell P, Moher D, Bouter LM (2007) Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC Medical Research Methodology, 7.

• Shorr, R., Griffin, M., Daugherty, J. et Ray, W. (1992). Opioid analgesics and the risk of hip fracture in the elderly: codeine and propoxyphene. Journal of Gerontology, 47, M111 à 115.

• Sigmon, S. (2006). Characterizing the emerging population of prescription opioid abusers. American Journal on Addictions, 15, p. 208 à 212.

• Silversides, A. (2009). Ontario takes aim at painkiller abuse. http://www.cmaj.ca/content/181/8/E141.full?sid=70d6f0b8-d2a5-4ea9-b15e-0a0e5228b2b5 (anglais seulement) [En ligne].

• Simoni-Wastila, L. (2000). The use of abusable prescription drugs: the role of gender. Journal of Women's Health and Gender-Based Medicine, 9, p. 289 à 297.

• Simoni-Wastila, L. (2001). Balancing diversion control and medical necessity: the case of prescription drugs and abuse potential. Substance Use and Misuse, 36, p. 1275 à 1296.

• Simoni-Wastila, L. et Strickler, G. (2004). Risk factors associated with problem use of prescription drugs. American Journal of Public Health, 94, p. 266 à 268.

• Simoni-Wastila, L., Ritter, G. et Strickler, G. (2004b). Gender and other factors associated with the nonmedical use of abusable prescription drugs. Substance Use and Misuse, 39, p. 1 à 23.

• Simoni-Wastila, L., Ross-Degnan, D., Mah, C., Gao, X., Brown, J., Cosler, L. et al. (2004a). A retrospective data analysis of the impact of the New York triplicate prescription program on benzodiazepine use in Medicaid patients with chronic psychiatric and neurologic disorders. Clinical Therapeutics, 26, p. 322 à 336.

• Smith, M. Y. et Woody, G. (2005). Nonmedical use and abuse of scheduled medications prescribed for pain, pain-related symptoms, and psychiatric disorders: patterns, user characteristics, and management options. Curr.Psychiatry Rep., 7, p. 337 à 343.

• Spiller, H., Lorenz, D., Bailey, E. et Dart, R. (2009). Epidemiological trends in abuse and misuse of prescription opioids. Jounal of Addictive Diseases, 28, p. 130 à 136.

• Sproule, B., Brands, B., Li, S. et Catz-Biro, L. (2009). Changing patterns in opioid addiction. Characterizing users of oxycodne and other opioids. Méd. fam. can., 55, p. 68 et 69.

• Sproule, B., Busto, U., Somer, G., Romach, M. et Sellers, E. (1999). Characteristics of dependent and nondependent regular users of codeine. Journal of Clinical Psychopharmacology, 19, p. 367 à 372.

• Stevens, K. et The Winnipeg Site Network Team (2006). CCENDU: Winnipeg 2006 Report Manitoba: Addictions Foundation of Manitoba, CCENDU.

• Stevenson, F., Barry, C., Britten, N., Barber, N. et Bradley, C. (2000). Doctor-patient communication about drugs: the evidence for shared decision-making. Social Science and Medicine, 50, p. 829 à 840.

• Strang, D. et Rashiq, S. (2005). The illicit sale of prescribed opioid medications in Edmonton, Alberta. Pain Research and Management, 10, p. 188 à 189.

• Subramaniam, G. et Stitzer, M. (2009). Clinical characteristics of treatment-seeking prescription opioid vs. heroin-using adolescents with opioid use disorder. Drug and Alcohol Dependence, 101, p. 13 à 19.

• Substance Abuse and Mental Health Administration (SAMHSA) (2008a). Drug Abuse Warning Network, 2006: National estimates of drug-related emergency department visits. http://www.samhsa.gov/data/DAWN/files/ED2006/DAWN2k6ED.htm (anglais seulement) [En ligne].

• Substance Abuse and Mental Health Administration (SAMHSA) (2008b). Results from the 2007 National Survey on Drug Use and Health: National findings. http://www.alcoholandcrime.org/images/uploads/pdf_research/nsduh_2007.pdf (anglais seulement) [En ligne].

• Surratt, H., Inciardi, J. et Kurtz, S. P. (2006). Prescription opioid abuse among drug-involved street-based sex workers. Journal of Opioid Management, 2, p. 283 à 289.

• Tyndall, M., Kerr, T., Zhang, R., King, E., Montaner, J. et Wood, E. (2006). Attendance, drug use patterns and referrals made from North America's first supervised injection facility. Drug and Alcohol Dependence, 83, p. 193 à 198.

• Wall, R., Rehm, J., Fischer, B., Brands, B., Gliksman, L., Stewart, J. et al. (2000). Social costs of untreated opiate use. Journal of Urban Health, 77, p. 688 à 722.

• Wardman, D., Khan, N. et el-Guebaly, N. (2002). Prescription medication use among an aboriginal population accessing addiction treatment. La Revue canadienne de psychiatrie, 47, p. 355 à 360.

• Wastila, L. et Bishop, C. (1996). The influence of multiple copy prescription programs on analgesic utilization. Journal of Pharmaceutical Care in Pain & Symptom Control, 4, p. 3 à 19.

• Webster, L., Bath, B. et Medve, R. (2009). Opioid formulations in development designed to curtail abuse: who is the target? Expert Opinion on Investigational Drugs, 18, p. 255 à 263.

• Weintraub, M., Singh, S., Byrne, L., Maharaj, K. et Guttmacher, L. (1991). Consequences of the 1989 New York State triplicate benzodiazepine prescription regulations. Journal of the American Medical Association, 266, p. 2392 à 2397.

• Wild, C., Wolfe, J., Newton-Taylor, M. et Kang, H. (2008). Prescription drug misuse in Edmonton and Alberta: A rapid assessment. http://www.uofaweb.ualberta.ca/amhrl/pdf/Wild_Wolfe_Newton-Taylor_Kang_2008_Prescription_Drug_Misuse.pdf (anglais seulement) [En ligne].

• Wild, T., Prakash, M., O'Connor, H., Taylor, M., Edwards, J. et Predy, G. (2003). Injection drug use in Edmonton's inner city: A multimethod study University of Alberta: Addiction and Mental Health Research Laboratory, Centre for Health Promotion Studies and Department of Public Health Sciences.

• Zacny, J., Bigelow, G., Compton, P., Foley, K., Iguchi, M. et Sannerud, C. (2003). College on Problems of Drug Dependence taskforce on prescription opioid non-medical use and abuse: position statement. Drug and Alcohol Dependence, 69, p. 215 à 232.

• Page précédente
• Table des matières